Kids with IBD and psoriasis may benefit from switching to ustekinumab
NCT ID NCT07529236
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 40 children with Crohn's disease or ulcerative colitis who developed severe psoriasis from anti-TNF drugs and switched to ustekinumab. Researchers will check if their digestive symptoms stay controlled and if their skin improves after 3-6 months. The goal is to see if this switch is a good option for managing both conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ustekinumab
- What this could lead to
- If successful, this could show that switching to ustekinumab is a safe and effective way to manage both IBD and treatment-related psoriasis in children.
- What could go wrong
- This is a small, observational study with only 40 children, so results may not apply to everyone. It also does not compare ustekinumab to other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY BOWEL DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nice
RECRUITINGNice, France, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can a new drug calm the Gut's overactive immune response in Crohn's?
- Can switching IBD meds heal the gut when symptoms are quiet?